Introduction and Objectives: The number of sensor-detected hypoglycemia (SDH) episodes depends on the hypoglycemia threshold used. We investigated the relationship between glucose threshold and the number and duration of events in the Hypo-METRICS dataset.
Methods: Individuals with insulin-treated diabetes wore a blinded continuous glucose monitor for 10 weeks. SDH was defined as 15 min below each threshold between 5 mmol/L (90 mg/dL) and 2.2 mmol/L (40 mg/dL) at 0.1 mmol/L increments. The number and average duration of episodes was calculated at each glucose threshold.
Results: Data from 599 (T1D=276 and T2D=323) people were analyzed; median age 56 years, HbA1c 7.4%. Event rate was higher for events between 3-5 mmol/L than < 3mmol/L (10.5 vs 1.1 episodes/week, p < 0.01) and average duration longer (63.1 vs 35.5 minutes/episode, p < 0.01). This is shown in Figure 1a and b. Each 0.1 mmol/L increment in hypoglycemia threshold resulted in 0.5 more episodes/week between 3-5 mmol/L vs 0.05 additional episodes/week at a threshold < 3 mmol/l (p < 0.01). Each 0.1 mmol/l increment in hypoglycemia threshold increased average duration by 3.1 minutes/episode between 3-5 mmol/l vs 0.4 minutes/episodes for those < 3 mmol/l (p < 0.01).
Conclusion: These results may be useful in understanding the alarm burden at different thresholds allowing personalization in proportion to individual risks.
J.J.C. Thomas: None. V. Koutroukas: Other Relationship; KelCon GmbH. P. Divilly: None. G. Martine-Edith: Other Relationship; Novo Nordisk A/S. N. Zaremba: None. S.A. Amiel: Advisory Panel; Vertex Pharmaceuticals Incorporated. Other Relationship; Sanofi. P. Choudhary: Advisory Panel; Abbott, Biolinq. Speaker's Bureau; Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Sanofi. Advisory Panel; Ypsomed AG, Vertex Pharmaceuticals Incorporated.
Hypo-RESOLVE (the consortium to which the Hypo-METRICS study belongs) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. Abbott Diabetes Care providedthe continuous glucose monitors used in the study